GoAI
Get started
Scholar Rock Holding Corporation logo

Scholar Rock Holding Corporation

SRRK

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$56.50

+$1.25 · +2.26%

Aug 21, 4:00 PM ET

SRRK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

30

Expensive

Momentum

68

Gaining

Sentiment

60

Mixed

Risk resilience

71

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David L. Hallal
Listed since
May 25, 2018
Employees
289

Market position

Day range

Current $56.50

52-week range

Current $56.50

Open
$55.38
Previous close
$55.25
Volume
1.16M
0.87× average
Average volume
1.33M
Average daily volume
Market cap
6.77B USD
Beta
0.67
Market reference 1
50-day average
$51.5891
+9.52% above average
200-day average
$46.4014
+21.76% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.84B USD
P/E (TTM)
-17.07×
P/B (TTM)
29.08×
P/S (TTM)
0×
EV / EBITDA
-13.1×
Earnings yield
-7.48%
Free cash flow yield
-5.95%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-153.95%
Return on assets
-93.49%
Return on invested capital
-108.53%

Financial health

Debt / equity
0.8×
Current ratio
6.95×
Altman Z-score
9.49
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends-228%-400%-572%-743%Gross margin, FY2021: -476.47%Gross margin, FY2022: -270.69%Operating margin, FY2021: -690.48%Operating margin, FY2022: -404.81%Net margin, FY2021: -700.46%Net margin, FY2022: -405.21%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -476.47%. Gross margin FY2022 -270.69%. Operating margin FY2021 -690.48%. Operating margin FY2022 -404.81%. Net margin FY2021 -700.46%. Net margin FY2022 -405.21%.

Income trends

Revenue

33.19M USD+76.41%

Operating income

−384.65M USD-52.60%

Net income

−377.94M USD-53.45%
Income trends across reported periods74.98M USD−92.16M USD−259.29M USD−426.43M USDRevenue, FY2021: 18.82M USDRevenue, FY2022: 33.19M USDOperating income, FY2021: −129.92M USDOperating income, FY2022: −134.37M USDOperating income, FY2023: −171.3M USDOperating income, FY2024: −252.05M USDOperating income, FY2025: −384.65M USDNet income, FY2021: −131.8M USDNet income, FY2022: −134.5M USDNet income, FY2023: −165.79M USDNet income, FY2024: −246.29M USDNet income, FY2025: −377.94M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 18.82M USD. Revenue FY2022 33.19M USD. Operating income FY2021 −129.92M USD. Operating income FY2022 −134.37M USD. Operating income FY2023 −171.3M USD. Operating income FY2024 −252.05M USD. Operating income FY2025 −384.65M USD. Net income FY2021 −131.8M USD. Net income FY2022 −134.5M USD. Net income FY2023 −165.79M USD. Net income FY2024 −246.29M USD. Net income FY2025 −377.94M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———33.19M USD18.82M USD
Cost of goods sold208.44M USD1.94M USD2.84M USD123.04M USD108.47M USD
Gross profit−208.44M USD−1.94M USD−2.84M USD−89.85M USD−89.65M USD
Research and development208.44M USD182.61M USD119.06M USD124.44M USD108.47M USD
Selling, general, and administrative176.21M USD67.5M USD49.4M USD42.62M USD40.27M USD
Operating expenses176.21M USD250.12M USD168.45M USD44.52M USD40.27M USD
Interest income13.9M USD12.68M USD———
Interest expense6.89M USD6.84M USD———
Depreciation and amortization1.66M USD1.94M USD2.84M USD2.99M USD2.63M USD
Operating income−384.65M USD−252.05M USD−171.3M USD−134.37M USD−129.92M USD
Net income−377.94M USD−246.29M USD−165.79M USD−134.5M USD−131.8M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 7 misses, 1 met estimate
Average EPS surprise
-8.48%
11 comparable reports
Latest EPS result
-0.84
Estimate -0.84 · Beat by 0.06%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.56-0.71-0.87-1.02Q1 '25MetQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.6, estimate -0.6, surprise 0.00%, Met estimate. Q2 2025, reported May 14, 2025: actual -0.67, estimate -0.63, surprise -6.35%, Miss. Q3 2025, reported Aug 6, 2025: actual -0.98, estimate -0.66, surprise -48.48%, Miss. Q4 2025, reported Nov 14, 2025: actual -0.9, estimate -0.835, surprise -7.76%, Miss. Q1 2026, reported Mar 3, 2026: actual -0.88, estimate -0.883, surprise +0.29%, Beat. Q2 2026, reported May 7, 2026: actual -0.83, estimate -0.82, surprise -1.22%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.84, estimate -0.841, surprise +0.06%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.87, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates12.59M8.41M4.22M42.5KQ1 '24No estimateQ3 '25EstimateQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2024, reported Mar 19, 2024: actual 11.66M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 6, 2025: actual —, estimate 55.56K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual —, estimate 50K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 3, 2026: actual —, estimate 1.83M USD, surprise —, Comparison unavailable. Q2 2026, reported May 7, 2026: actual —, estimate 5M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual —, estimate 70K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 13, 2026: actual —, estimate 75K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$62.14

9.98% upside
Past 12 months12-month forecastHigh $76.00Average $62.14Low $55.00

Rating distribution

12 ratings
Strong buy00%
Buy12100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

9 institutions

SRRK news

businesswire.com

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its…

Read source
marketbeat.com

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

Scholar Rock NASDAQ: SRRK CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitted…

Read source
businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly…

Read source
reuters.com

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its application seeking ​FDA approval for a rare neuromuscular disease drug.

Read source
businesswire.com

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its…

Read source
marketbeat.com

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock NASDAQ: SRRK said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the company prepares for a…

Read source

SRRK peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SRRK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
162.7M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
157.01M
Weight
0.19%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
130.74M
Weight
1.15%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
54.18M
Weight
0.06%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
54.02M
Weight
0.36%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
39.77M
Weight
0.38%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
29.67M
Weight
0.17%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
26.29M
Weight
0.11%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research SRRK

research.disclaimer